Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $15.57

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $15.57.

Several analysts have commented on the stock. JMP Securities reissued a “market outperform” rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a research report on Friday, January 31st. Evercore ISI increased their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price target for the company. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $11.00 price objective (up from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.70 on Friday. The firm has a market cap of $1.61 billion, a PE ratio of -12.62 and a beta of 1.85. The company has a 50-day moving average of $8.14 and a 200 day moving average of $7.85. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. The business’s revenue was up 40.8% on a year-over-year basis. During the same period last year, the firm posted $0.28 earnings per share. Sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $33,000. Venturi Wealth Management LLC acquired a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $46,000. R Squared Ltd acquired a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $48,000. KBC Group NV increased its holdings in BioCryst Pharmaceuticals by 80.1% in the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after buying an additional 4,537 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $80,000. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.